Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Adicionar filtros








Intervalo de ano
1.
Bol. méd. Hosp. Infant. Méx ; 79(6): 363-368, Nov.-Dec. 2022. tab
Artigo em Inglês | LILACS-Express | LILACS | ID: biblio-1429926

RESUMO

Abstract Background: Pregnancy-induced hypertension (PIH) has been related to impaired fetal growth, possibly by affecting hematopoiesis. This study aimed to analyze the most frequent hematological alterations in preterm infants born to mothers with PIH. Methods: We conducted a cross-sectional study in newborns born to mothers with PIH. We reviewed 130 hemograms of preterm infants: 45 from mothers with PIH, 71 with preeclampsia, and 14 with HELLP syndrome (hemolysis, elevated liver enzymes, and low platelet count). Normality, cytosis conditions, or cytopenia values were adjusted for gestational ages. Differences between groups were analyzed with classical and Bayesian statistics (BF01 = null/alternative hypothesis ratio). Results: Anemia was found in only 1.2% of newborns. In the white blood cell count, the most frequent finding was lymphopenia (56.2%) and monocytosis (38.5%) (p = 0.6, FB01 = 249 y p = 0.81, FB01 = 19.9). Thrombocytopenia was found in 12.5% (p = 0.56, FB01 = 67). No significant differences were observed among PIH groups. Conclusions: Hematological alterations of newborns born to mothers with PIH are frequent and do not show a distinct pattern related to the severity of the affection in the mother. We recommend a full hematological evaluation in these preterm neonates.


Resumen Introducción: La enfermedad hipertensiva del embarazo (EHE) se ha relacionado con alteraciones en el crecimiento fetal, posiblemente porque afecta la hematopoyesis. El objetivo de este estudio fue analizar las alteraciones hematológicas más frecuentes en los recién nacidos prematuros hijos de madres con EHE. Métodos: Se llevó a cabo un estudio transversal en recién nacidos de madres con EHE. Se revisaron los hemogramas de 130 neonatos prematuros: 45 madres con hipertensión gestacional, 71 con pre-eclampsia y 14 con síndrome de HELLP (hemólisis, enzimas hepáticas elevadas y bajo recuento de plaquetas). Las cifras de normalidad, condiciones de citosis o citopenia fueron ajustadas a las edades gestacionales. Las diferencias entre los grupos se analizaron con estadística clásica y bayesiana (FB01= relación hipótesis nula/alterna). Resultados: Se encontró anemia en solo el 1.2% de los recién nacidos. En la serie blanca el hallazgo más frecuente fue la linfopenia (56.2%) y monocitosis (38.5%) (p = 0.6, FB01 = 249 y p = 0.81, FB01 = 19.9). La plaquetopenia se encontró en el 12.5% (p = 0.56, FB01 = 67). No se observaron diferencias significativas entre los grupos de EHE. Conclusiones: Las alteraciones hematológicas en recién nacidos de madres con EHE son frecuentes sin mostrar un patrón distinto con relación a la gravedad del padecimiento de la madre. Aun así, es recomendable la valoración hematológica en estos neonatos.

2.
López-Arroyo, José L.; Pérez-Zúñiga, Juan M.; Merino-Pasaye, Laura E.; Saavedra-González, Azucena; Alcivar-Cedeño, Luisa María; Álvarez-Vera, José Luis; Anaya-Cuellar, Irene; Arana-Luna, Luara L.; Ávila-Castro, David; Bates-Martín, Ramón A.; Cesarman-Maus, Gabriela; Chávez-Aguilar, Lénica A.; Peña-Celaya, José A. de la; Espitia-Ríos, María E.; Estrada-Domínguez, Patricia; Fermín-Caminero, Denisse; Flores-Patricio, Willy; García Chávez, Jaime; García-Lee, María T.; González-Pérez, María del Carmen; González-Rubio, María del Carmen; González-Villareal, María Guadalupe; Ramírez-Moreno, Fabiola; Hernández-Colin, Ana K.; Hernández-Ruiz, Eleazar; Herrera-Olivares, Wilfrido; Leyto-Cruz, Faustino; Loera-Fragoso, Sergio; Martínez-Ríos, Annel; Miranda-Madrazo, María R.; Morales-Hernández, Alba; Nava-Villegas, Lorena; Orellana-Garibay, Juan J.; Palma-Moreno, Orlando G.; Paredes-Lozano, Eugenia P.; Peña-Alcántara, Paula; Pérez-Lozano, Uendy; Pichardo-Cepín, Yayra M.; Reynoso-Pérez, Ana Carolina; Rodríguez-Serna, Mishel; Rojas-Castillejos, Flavio; Romero-Rodelo, Hilda; Ruíz-Contreras, Josué I.; Segura-García, Adela; Silva-Vera, Karina; Soto-Cisneros, Paulina M.; Tapia-Enríquez, Ana L.; Tavera-Rodríguez, Martha G.; Teomitzi-Sánchez, Óscar; Tepepa-Flores, Fredy; Valencia-Rivas, María D.; Valle-Cárdenas, Teresa; Varela-Constantino, Ana; Javier-Morales, Adrián; Martínez-Ramírez, Mario A.; Tena-Cano, Sergio; Terrazas-Marín, Ricardo; Vilchis-González, Shendel P.; Villela-Peña, Atenas; Mena-Zepeda, Verónica; Alvarado Ibarra, Martha.
Gac. méd. Méx ; 157(supl.1): S1-S37, feb. 2021. tab, graf
Artigo em Espanhol | LILACS-Express | LILACS | ID: biblio-1375490

RESUMO

resumen está disponible en el texto completo


Abstract Hemophilia is a hemorrhagic disorder with a sex-linked inherited pattern, characterized by an inability to amplify coagulation due to a deficiency in coagulation factor VIII (hemophilia A or classic) or factor IX (hemophilia B). Sequencing of the genes involved in hemophilia has provided a description and record of the main mutations, as well as a correlation with the various degrees of severity. Hemorrhagic manifestations are related to levels of circulating factor, mainly affecting the musculoskeletal system and specifically the large joints (knees, ankles and elbows). This document is a review and consensus of the main genetic aspects of hemophilia, from the inheritance pattern to the concept of women carriers, physiopathology and classification of the disorder, the basic and confirmation studies when hemophilia is suspected, the various treatment regimens based on infusion of the deficient coagulation factor as well as innovative factor-free therapies and recommendations for the management of complications associated with treatment (development of inhibitors and/or transfusion transmitted infections) or secondary to articular hemorrhagic events (hemophilic arthropathy). Finally, relevant reviews of clinical and treatment aspects of hemorrhagic pathology charachterized by acquired deficiency of FVIII secondary to neutralized antibodies named acquired hemophilia.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA